Safety of human papillomavirus vaccines: A review

Expert Opinion on Drug Safety

Volumn 14, Issue 5, 2015, Pages 697-712

  Stillo, Michela ^a   Carrillo Santisteve, Paloma ^b   Lopalco, Pier Luigi ^b  

^a UNIVERSITY OF TURIN   (Italy)

^b ECDC   (Sweden)

Author keywords

Adverse events; Human papillomavirus; Safety; Vaccine

Indexed keywords

WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18;

ABDOMINAL PAIN; AORTA RUPTURE; APPENDICITIS; COUGHING; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MECHANISM; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DYSPNEA; FAINTNESS; GASTROINTESTINAL SYMPTOM; GUILLAIN BARRE SYNDROME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; INJECTION SITE PAIN; INJECTION SITE REACTION; INTERPERSONAL COMMUNICATION; LICENSING; LISTLESSNESS; META ANALYSIS (TOPIC); MYALGIA; NAUSEA; OVARY CYST; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POPULATION GROUP; PREVENTIVE HEALTH SERVICE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SEIZURE; SLEEP DISORDER; SORE THROAT; SPONTANEOUS ABORTION; SWELLING; SYSTEMATIC REVIEW (TOPIC); SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTOPENIA; TREATMENT CONTRAINDICATION; URTICARIA; VACCINATION; VENOUS THROMBOEMBOLISM; WART VIRUS; PAPILLOMAVIRUS INFECTIONS; POSTMARKETING SURVEILLANCE; PROCEDURES;

HUMAN PAPILLOMAVIRUS RECOMBINANT VACCINE QUADRIVALENT, TYPES 6, 11, 16, 18; HUMANS; IMMUNIZATION PROGRAMS; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PRODUCT SURVEILLANCE, POSTMARKETING; VACCINATION;

EID: 84928337401     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2015.1013532     Document Type: Review

References (107)

1. WHO. 2012. Available from: http://globocan.iarc.fr/Pages/bar-sex-site-sel.aspx [Cited 17 December 2014]
2. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in European Union countries-an update. 2012
3. CDC Centre for disease prevention and control. USA 2014; Available from: http://www.cdc.gov [Updated 2014]
4. EMA. Update on 2014; Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human-med-000694.jsp&mid=WC0b01ac058001d124 [Updated 6 October 2014]
5. Gamble HL, Klosky JL, Parra GR, Randolph ME. Factors influencing familial decision-making regarding human papillomavirus vaccination. J Pediatr Psychol 2010;35(7):704-15
6. Sotiriadis A, Dagklis T, Siamanta V, et al. Increasing fear of adverse effects drops intention to vaccinate after the introduction of prophylactic HPV vaccine. Arch Gynecol Obstet 2012;285(6):1719-24
7. Rambout L, Tashkandi M, Hopkins L, Tricco AC. Self-reported barriers and facilitators to preventive human papillomavirus vaccination among adolescent girls and young women: a systematic review. Prev Med 2014;58:22-32
8. Angelo MG, Zima J, Tavares Da Silva F, et al. Post-licensure safety surveillance for human papillomavirus-16/18-AS04-adjuvanted vaccine: more than 4 years of experience. Pharmacoepidemiol Drug Saf 2014;23(5):456-65
9. Gold MS, McIntyre P. Human papillomavirus vaccine safety in Australia: experience to date and issues for surveillance. Sex Health 2010;7(3):320-4
10. Markowitz LE, Dunne EF, Saraiya M, et al. Human papillomavirus vaccination. MMWR Recomm Rep 2014;63(RR-05):1-30
11. Brotherton JM. Safety of the quadrivalent human papillomavirus vaccine. BMJ 2013;347:f5631
12. Brotherton JM. Human papillomavirus vaccination: Where are we now? J Paediatr Child Health 2014.50(12):959-65
13. Stokley S, Jeyarajah J, Yankey D, et al. Human papillomavirus vaccination coverage among adolescents, 2007-2013, and postlicensure vaccine safety monitoring, 2006-2014-United States. MMWR Morb Mortal Wkly Rep 2014;63(29):620-4
14. Chen J, Ni G, Liu XS. Papillomavirus virus like particle-based therapeutic vaccine against human papillomavirus infection related diseases: immunological problems and future directions. Cell Immunol 2011;269(1):5-9
15. EMA product information. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000721/WC500024632.pdf
16. EMA product information Cervarix. Available from: http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/000703/WC500021142.pdf
17. FDA. Highlights of prescribing informationrevised 2014. 2014. Available from: http://www.fda. gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM111263.pdf
18. FDA. Highlights of prescribing information (Cervarix). 2014. Available from: http://www.fda. gov/downloads/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM186981.pdf
19. cervicalcancer.org. Global Progress in HPV Vaccination. updated September 2014 Available from: http://www.cervicalcanceraction.org/comments/comments3.php; [Cited 2014]
20. EMA. 2008.updated 14 August 201417 Dec 2014 Available from: http://www.ema. europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human-med-000805. jsp&mid=WC0b01ac058001d124
21. Vaccine Schedule. Internet 2013. Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler. aspx [Cited 17 December 2014]
22. Einstein MH, Baron M, Levin MJ, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011;7(12):1343-58
23. Petaja T, Pedersen C, Poder A, et al. Long-term persistence of systemic and mucosal immune response to HPV-16/18 AS04-adjuvanted vaccine in preteen/adolescent girls and young women. Int J Cancer 2011;129(9):2147-57
24. Basu P, Banerjee D, Singh P, et al. Efficacy and safety of human papillomavirus vaccine for primary prevention of cervical cancer: a review of evidence from phase III trials and national programs. South Asian J Cancer 2013;2(4):187-92
25. Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine 2012;30(Suppl 5):F123-38
26. Naud PS, Roteli-Martins CM, De Carvalho NS, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: Final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother 2014;10(8):2147-62
27. Harper DM, Franco EL, Wheeler CM, et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 2006;367(9518):1247-55
28. Dillner J, Kjaer SK, Wheeler CM, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ 2010;341:c3493
29. GlaxoSmithKline. Cervarix: Summary of product Characteristics. 2014; Available from: http://www.medicines.org.uk/emc/medicine/20204. [Updated 8 Decemer 2014]
30. Villa LL, Costa RL, Petta CA, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer 2006;95(11):1459-66
31. David MP, Van Herck K, Hardt K, et al. Long-term persistence of anti-HPV-16 and-18 antibodies induced by vaccination with the AS04-adjuvanted cervical cancer vaccine: modeling of sustained antibody responses. Gynecol Oncol 2009;115(3 Suppl):S1-6
32. Mariani L, Venuti A. HPV vaccine: an overview of immune response, clinical protection, and new approaches for the future. J Transl Med 2010;8:105
33. Newman PA, Logie CH, Doukas N, Asakura K. HPV vaccine acceptability among men: a systematic review and meta-analysis. Sex Transm Infect 2013;89(7):568-74
34. Hillman RJ, Giuliano AR, Palefsky JM, et al. Immunogenicity of the quadrivalent human papillomavirus (type 6/11/16/18) vaccine in males 16 to 26 years old. Clin Vaccine Immunol 2012;19(2):261-7
35. Munoz N, Manalastas R Jr, Pitisuttithum P, et al. Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial. Lancet 2009;373(9679):1949-57
36. Castellsague X, Munoz N, Pitisuttithum P, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer 2011;105(1):28-37
37. Chen RT. Vaccine risks: real, perceived and unknown. Vaccine 1999.17(Suppl 3):S41-S6
38. WHO safety training. 2014; Available from: http://vaccine-safety-training.org/
39. Lu B, Kumar A, Castellsague X, Giuliano AR. Efficacy and safety of prophylactic vaccines against cervical HPV infection and diseases among women: a systematic review & meta-analysis. BMC Infect Dis 2011;11:13
40. Agorastos T, Chatzigeorgiou K, Brotherton JM, Garland SM. Safety of human papillomavirus (HPV) vaccines: a review of the international experience so far. Vaccine 2009;27(52):7270-81
41. Macartney KK, Chiu C, Georgousakis M, Brotherton JM. Safety of human papillomavirus vaccines: a review. Drug Saf 2013;36(6):393-412
42. Weber SK, Schlagenhauf P. Childhood vaccination associated adverse events by sex: A literature review. Travel Med Infect Dis 2014;12(5):459-80
43. Block SL, Brown DR, Chatterjee A, et al. Clinical trial and post-licensure safety profile of a prophylactic human papillomavirus (types 6, 11, 16, and 18) l1 virus-like particle vaccine. Pediatr Infect Dis J 2010;29(2):95-101
44. Gasparini R, Bonanni P, Levi M, et al. Safety and tolerability of bivalent HPV vaccine: an Italian post-licensure study. Hum Vaccin 2011;7(Suppl):136-46
45. Rambout L, Hopkins L, Hutton B, Fergusson D. Prophylactic vaccination against human papillomavirus infection and disease in women: a systematic review of randomized controlled trials. CMAJ 2007;177(5):469-79
46. Paavonen J, Jenkins D, Bosch FX, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007;369(9580):2161-70
47. Medina DM, Valencia A, de Velasquez A, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls. J Adolescent Health 2010;46(5):414-21
48. VAERS website. Vaccine Adverse Events Reporting system: centers for Disease Control and Prevention (CDC), the Food and Drug Administration (FDA), agencies of the U.S. Department of Health and Human Service. Available from: https://vaers.hhs.gov/index
49. Public Health Agency of Canada. Adverse events following immunization reporting form: public Health Agency of Canada. Available from: http://www.phac-aspc.gc.ca/[Cited October 2014]
50. Medicines and Health products Regulatory Agency (MHRA). Yellowcard: medicines and Health products Regulatory Agency (MHRA). Available from: https://yellowcard.mhra.gov.uk/yellowcards/reportmediator/[Cited 17 December 2014]
51. Medicines and Healthcare products Regulatory Agency (MHRA). Public assessment report. Cervarix (HPV vaccine): update on UK safety experience at the end of 4 years use in the HPV routine immunisation programme: Medicines and Healthcare products Regulatory Agency (MHRA). Available from: http://www.mhra.gov.uk/[Cited 17 December 2014]
52. Australian Goverment. Australian TGA system for adverse events surveillance: australian Government. Available from: http://www.tga.gov.au/safety/problem-medicine.htm [Cited October 2014]
53. Lindquist M. Use of triage strategies in the WHO signal-detection process. Drug Saf 2007;30(7):635-7
54. Baggs J, Gee J, Lewis E, et al. The vaccine safety datalink: a model for monitoring immunization safety. Pediatrics 2011;127(Suppl 1):S45-53
55. Angelo MG, David MP, Zima J, et al. Pooled analysis of large and long-term safety data from the human papillomavirus-16/18-AS04-adjuvanted vaccine clinical trial programme. Pharmacoepidemiol Drug Saf 2014;23(5):466-79
56. Khatun S, Akram Hussain SM, Chowdhury S, et al. Safety and immunogenicity profile of human papillomavirus-16/18 AS04 adjuvant cervical cancer vaccine: a randomized controlled trial in healthy adolescent girls of Bangladesh. Jpn J Clin Oncol 2012;42(1):36-41
57. Skinner SR, Szarewski A, Romanowski B, et al. Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study. The Lancet 2014;384(9961):2213-27
58. Reisinger KS, Block SL, Lazcano-Ponce E, et al. Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial. Pediatr Infect Dis J 2007;26(3):201-9
59. van Klooster TM, Kemmeren JM, van der Maas NA, de Melker HE. Reported adverse events in girls aged 13-16 years after vaccination with the human papillomavirus (HPV)-16/18 vaccine in the Netherlands. Vaccine 2011;29(28):4601-7
60. Levi M, Bonanni P, Burroni E, et al. Evaluation of bivalent human papillomavirus (HPV) vaccine safety and tolerability in a sample of 25 year old Tuscan women. Hum Vaccin Immunother 2013;9(7):1407-12
61. Klein NP, Hansen J, Chao C, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med 2012;166(12):1140-8
62. Slade BA, Leidel L, Vellozzi C, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. Jama 2009;302(7):750-7
63. Labadie J. Postlicensure safety evaluation of human papilloma virus vaccines. Int J Risk Saf Med 2011;23(2):103-12
64. Gee J, Naleway A, Shui I, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine 2011;29(46):8279-84
65. FDA safety. Available from: http://www.fda.gov/Safety/MedWatch/HowToReport/ucm053087.htm [cited 17 December 2014]
66. European parliament and the council. Dir 2001/83/EC art.1(12) 2001. Available from: http://www.ema. europa.eu/docs/en-GB/document-library/Regulatory-and-procedural-guideline/2009/10/WC500004481.pdf
67. Schwarz TF, Huang LM, Lin TY, et al. Long-term immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in 10-14 year old girls: Open six-year follow-up of an initial observer-blinded, randomized trial. Pediatr Infect Dis J 2014;33(12):1255-61
68. Harris T, Williams DM, Fediurek J, et al. Adverse events following immunization in Ontario's female school-based HPV program. Vaccine 2014;32(9):1061-6
69. Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, et al. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ 2013;347:f5906
70. Scheller NM, Pasternak B, Svanstrom H, Hviid A. Quadrivalent human papillomavirus vaccine and the risk of venous thromboembolism. Jama 2014;312(2):187-8
71. Pellegrino P, Carnovale C, Pozzi M, et al. On the relationship between human papilloma virus vaccine and autoimmune diseases. Autoimmun Rev 2014;13(7):736-41
72. Souayah N, Michas-Martin PA, Nasar A, et al. Guillain-barre syndrome after gardasil vaccination: data from vaccine adverse event reporting system. 2006-2009. Vaccine 2011;29(5):886-9
73. Ojha RP, Jackson BE, Tota JE, et al. Guillain-Barre syndrome following quadrivalent human papillomavirus vaccination among vaccine-eligible individuals in the United States. Hum Vaccin Immunother 2014;10(1):232-7
74. Chao C, Klein NP, Velicer CM, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med 2012;271(2):193-203
75. Slade BA, Gee J, Broder KR, Vellozzi C. Comment on the contribution by Souayah et al., Guillain-Barre syndrome after Gardasil vaccination: data from Vaccine Adverse Event Reporting System 2006-2009. Vaccine 2011;29(5):865-6
76. Centers for Disease Control and Prevention. Vaccine safety: centers for Disease Control and Prevention. Available from: http://www.cdc.gov/vaccinesafety/Vaccines/HPV/Index. html#data [Cited 17 December 2014]
77. Grimaldi-Bensouda L, Guillemot D, Godeau B, et al. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects. J Intern Med 2014;275(4):398-408
78. Tam LS, Chan AY, Chan PK, et al. Increased prevalence of squamous intraepithelial lesions in systemic lupus erythematosus: association with human papillomavirus infection. Arthritis Rheum 2004;50(11):3619-25
79. Soldevilla HF, Briones SF, Navarra SV. Systemic lupus erythematosus following HPV immunization or infection? Lupus 2012;21(2):158-61
80. Gatto M, Agmon-Levin N, Soriano A, et al. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol 2013;32(9):1301-7
81. Soybilgic A, Onel KB, Utset T, et al. Safety and immunogenicity of the quadrivalent HPV vaccine in female systemic lupus erythematosus patients aged 12 to 26 years. Pediatr Rheumatol Online J 2013;11:29
82. Zhu FC, Chen W, Hu YM, et al. Efficacy, immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese women aged 18-25 years: results from a randomized controlled trial. Int J Cancer 2014;135(11):2612-22
83. Garnock-Jones KP, Giuliano AR. Quadrivalent human papillomavirus (HPV) types 6, 11, 16, 18 vaccine: for the prevention of genital warts in males. Drugs 2011;71(5):591-602
84. Fairweather D, Rose NR. Women and autoimmune diseases. Emerg Infect Dis 2004;10(11):2005-11
85. Luna J, Plata M, Gonzalez M, et al. Long-term follow-up observation of the safety, immunogenicity, and effectiveness of Gardasil in adult women. PLoS One 2013;8(12):e83431
86. Moscicki AB, Ellenberg JH, Farhat S, Xu J. Persistence of human papillomavirus infection in HIV-infected and-uninfected adolescent girls: risk factors and differences, by phylogenetic type. J Infect Dis 2004;190(1):37-45
87. Palefsky J. Human papillomavirus infection in HIV-infected persons. Top HIV Med 2007;15(4):130-3
88. Palefsky JM. HPV infection in men. Dis Markers 2007;23(4):261-72
89. Levin MJ, Moscicki AB, Song LY, et al. Safety and immunogenicity of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine in HIV-infected children 7 to 12 years old. J Acquir Immune Defic Syndr 2010;55(2):197-204
90. Denny L, Hendricks B, Gordon C, et al. Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in HIV-positive women in South Africa: a partially-blind randomised placebo-controlled study. Vaccine 2013;31(48):5745-53
91. Kahn JA, Xu J, Kapogiannis BG, et al. Immunogenicity and safety of the human papillomavirus 6, 11, 16, 18 vaccine in HIV-infected young women. Clin Infect Dis 2013;57(5):735-44
92. Wilkin T, Lee JY, Lensing SY, et al. Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men. J Infect Dis 2010;202(8):1246-53
93. Toft L, Storgaard M, Muller M, et al. Comparison of the immunogenicity and reactogenicity of Cervarix and Gardasil human papillomavirus vaccines in HIV-infected adults: a randomized, double-blind clinical trial. J Infect Dis 2014;209(8):1165-73
94. Kojic EM, Kang M, Cespedes MS, et al. Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 2014;59(1):127-35
95. Giacomet V, Penagini F, Trabattoni D, et al. Safety and immunogenicity of a quadrivalent human papillomavirus vaccine in HIV-infected and HIV-negative adolescents and young adults. Vaccine 2014;32(43):5657-61
96. Presidencia de la repbulica de Colombia. Presidente Santos pide a Ministro de Salud ir a El Carmen de Bolívar para explicar alcances de vacuna contra el VPH 2014. p. Communication from the President of the Republic of Colombia regarding the events taking place in Carmen Bolivar related to HPV vaccination
97. Fox News Latino. President: There Is Not Link Between Mystery Illness And HPV Vaccine. Fox news latino. on-line edition ed 2014
98. Adetunji J. Schoolgirl dies after cervical cancer vaccination. Guardian News and Media Limited, UK; 2009
99. Bowcott O. Girl who died after cervical cancer injection had tumour in her chest. The Guardian; 2009
100. Sheridan A, White J. Annual HPV vaccine coverage in England in 2009/2010. Department of Health, London, UK; 2011
101. Reuters web page. UPDATE 1-Spain halts batch of Merck's Gardasil. 2009. Available from: http://www.reuters.com/article/2009/02/10/tb-merck-gardasil-suspension-idUSLA56308620090210
102. Morimoto A, Ueda Y, Egawa-Takata T, et al. Effect on HPV vaccination in Japan resulting from news report of adverse events and suspension of governmental recommendation for HPV vaccination. Int J Clin Oncol 2014. [Epub ahead of print]
103. Peres J. For cancers caused by HPV, two vaccines were just the beginning. J Natl Cancer Inst 2011;103(5):360-2
104. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007;356(19):1928-43
105. Paavonen J, Naud P, Salmeron J, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a doubleblind, randomised study in young women. Lancet 2009;374(9686):301-14
106. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002;347(21):1645-51
107. Mao C, Koutsky LA, Ault KA, et al. Efficacy of human papillomavirus-16 vaccine to prevent cervical intraepithelial neoplasia: a randomized controlled trial. Obstet Gynecol 2006;107(1):18-27